Description
iXB-322 is an experimental, low-dose interferon-alpha wafer designed for sublingual delivery to prevent and treat various respiratory viral infections, including COVID-19, influenza, and respiratory syncytial virus (RSV). This pharmaceutical candidate leverages the proprietary WaferiX platform to provide a convenient, fast-acting, and non-invasive alternative to traditional injection-based interferon treatments in the immunology and wellness sector.
Best for
respiratory viral illness prevention, non-invasive medication users, immunology therapy and specialty pharmaceutical treatments